3/4/2021 8:42:08 AM
Gilead Sciences Completes Transaction To Acquire MYR GmbH
2/10/2021 5:33:58 PM
Kite Announces Findings From New Analysis Of ZUMA-1 Trial Of Yescarta
2/10/2021 9:04:18 AM
Galapagos, Gilead Discontinue ISABELA Phase 3 Trials In Idiopathic Pulmonary Fibrosis
2/4/2021 4:09:02 PM
Gilead Sciences Inc. (GILD) Declares $ 0.71 Dividend for Q1 21, Record Date 3/15/2021
2/4/2021 4:03:40 PM
Gilead Sciences Q4 EPS $1.23; Non-GAAP EPS $2.19
2/1/2021 6:03:16 AM
Gilead, Gritstone Collaborate Utilizing Vaccine Platform Technology For HIV Cure
1/19/2021 8:06:52 AM
Francesco Marincola Joins Kite As Worldwide Head Of Cell Therapy Research
1/12/2021 8:18:42 AM
Gilead, Vir To Explore Combination Strategies For Functional Cure For Chronic Hepatitis B Virus
1/12/2021 8:04:32 AM
Gilead And Vir Collaborate To Explore Combination Strategies For Functional Cure For Chronic Hepatitis B Virus
1/11/2021 6:11:08 AM
Gilead Sciences Inc. (GILD) Has Raised Its FY20 EPS Estimate To 6.98 - 7.08 From 6.25 - 6.60
1/11/2021 6:04:28 AM
Gilead Sciences Now Sees Non-GAAP EPS View Of $6.98 To $7.08 For 2020
1/6/2021 8:14:19 AM
Kite, Oxford BioTherapeutics Enter Collaboration To Evaluate 5 Novel Targets For Hematologic And Solid Tumor Indications